北京德恒（杭州）律师事务所 关于杭州安杰思医学科技股份有限公司 2025年第二次临时股东大会的 法律意见 德恒律师事务所 DeHeng Law Offices 电话:0571-86508080 传真:0571-87357755 邮编:310020 杭州市上城区新业路 200 号华峰国际商务大厦 10、11 楼 北京德恒(杭州)律师事务所 关于杭州安杰思医学科技股份有限公司 2025 年第二次临时股东大会的法律意见 北京德恒(杭州)律师事务所 关于杭州安杰思医学科技股份有限公司 2025年第二次临时股东大会的 法律意见 致:杭州安杰思医学科技股份有限公司 北京德恒(杭州)律师事务所受杭州安杰思医学科技股份有限公司(以下简 称"公司")委托,指派冯琳律师、杨洋律师(以下简称"本所律师")出席公 司 2025 年第二次临时股东大会(以下简称"本次股东大会"),对本次股东大会 的合法性进行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》〈以下简称"《证券法》"）、《上市公司股东会规 则》等现行有效的法律、法规和规范性文件以及《杭州安杰思医学科技股份有限 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-060 杭州安杰思医学科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 26 日 （二） 股东大会召开的地点：杭州市临平区兴中路 389 号三楼 302 会议室 1、 公司在任董事5人，出席5人； 2、 董事会秘书张勤华的出席了本次会议；其他高管盛跃渊、韩春琦列席了本次 会议。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 52 | | --- | --- | | 普通股股东人数 | 52 | | 2、出席会议的股东所持有的表决权数量 | 54,785,419 | | 普通股股东所持有表决权数量 | 54,785,419 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 67.671 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 一、董事会会议召开情况 杭州安杰思医学科技股份有限公司（以下简称"公司"）第三届董事会第五 次会议于 2025 年 9 月 26 日以现场结合通讯的方式在公司九楼会议室召开。本 次会议通知及相关材料已于 2025 年 9 月 19 日以专人送达方式通知公司全体董 事，与会的各位董事已知悉与所议事项相关的必要信息。会议由董事长张承主 持，会议应到董事 5 人，实际出席董事 5 人，公司高级管理人员列席了本次会 议。本次会议的召集和召开程序符合《公司法》和《公司章程》的有关规定。 会议审议通过以下议案并形成决议： 二、董事会会议审议情况 （一）审议通过了《关于选举代表公司执行公司事务的董事的议案》 根据《公司法》《上市公司章程指引（2025 年修订）》等法律法规及《公司 章程》的规定，董事会同意选举公司现任董事长张承先生为代表公司执行公司事 务的董事并担任公司法定代表人，任期自本次董事会审议通过之日起至第三届董 事会届满之日止。 证券代码：688581 证券简称：安杰思 公告编 ...

Group 1 - The core viewpoint of the news is that Anjisi has shown a slight decline in stock price and trading volume, with specific details on financing and margin trading activities [1] - As of September 23, Anjisi's financing balance is 104 million yuan, accounting for 3.43% of its market capitalization, which is below the 20th percentile level over the past year, indicating a low financing level [1] - The company has not engaged in any short selling activities on September 23, with a margin balance of 0, which is at the 90th percentile level over the past year, indicating a high level of short selling potential [1] Group 2 - As of September 20, the number of shareholders in Anjisi decreased by 15.19% to 4,779, while the average circulating shares per person increased by 17.91% to 8,666 shares [2] - For the first half of 2025, Anjisi reported a revenue of 302 million yuan, representing a year-on-year growth of 14.56%, and a net profit attributable to shareholders of 126 million yuan, with a growth rate of 1.26% [2] - Since its A-share listing, Anjisi has distributed a total of 239 million yuan in dividends [2]

Core Insights - The company achieved total revenue of 302 million yuan in H1 2025, representing a year-on-year growth of 14.56%, with a net profit attributable to shareholders of 126 million yuan, up 1.26%, while the gross margin declined by 1.35 percentage points [1] - Domestic revenue faced short-term pressure, while overseas revenue showed steady growth, with 14 new overseas clients added in H1 2025 [1] - The company is focusing on independent innovation and enhancing its R&D capabilities, with R&D expenses reaching 344.6 million yuan, a 33.29% increase year-on-year, and an R&D expense ratio of 11.39% [1][2] Revenue Breakdown - Domestic revenue for H1 2025 was 140 million yuan, a 10.50% increase, accounting for 46.19% of total revenue, with a slight gross margin increase of 0.18 percentage points [1] - Overseas revenue reached 163 million yuan, growing by 18.28% and making up 53.81% of total revenue [1] R&D and Talent Development - The company expanded its R&D team to 187 personnel, a 47.24% increase year-on-year, with 42.25% holding bachelor's degrees and 40.11% holding master's degrees or higher [2] - The company obtained 45 new product registration certificates in H1 2025, including 26 new domestic and international registrations, supporting its global sales strategy [1] Future Projections - Revenue projections for 2025-2027 are 769 million, 942 million, and 1.147 billion yuan, with expected growth rates of 20.8%, 22.4%, and 21.8% respectively [2] - Net profit projections for the same period are 327 million, 387 million, and 464 million yuan, with growth rates of 11.6%, 18.1%, and 19.8% respectively [2]

Investment Rating - The report maintains an "Accumulate" rating for the company [5][11] Core Views - The company experienced a total revenue of 302 million yuan in H1 2025, representing a year-on-year growth of 14.56%, while the net profit attributable to shareholders was 126 million yuan, with a growth of 1.26%. The gross margin decreased by 1.35 percentage points [1][5] - Domestic performance is under short-term pressure, while overseas growth remains robust. The company is actively expanding its overseas partnerships and has added 14 new overseas clients in H1 2025 [1][2] - The company invested 344.6 million yuan in R&D in H1 2025, with an R&D expense ratio of 11.39%, an increase of 1.6 percentage points year-on-year, and R&D investment grew by 33.29% [2] Summary by Sections Financial Performance - In H1 2025, domestic revenue was 140 million yuan, up 10.50% year-on-year, accounting for 46.19% of total revenue, with a gross margin increase of 0.18 percentage points. Overseas revenue reached 163 million yuan, growing by 18.28% year-on-year, making up 53.81% of total revenue [1] - The company forecasts revenues of 769 million yuan, 942 million yuan, and 1.147 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 20.8%, 22.4%, and 21.8% [2][3] R&D and Innovation - The company is focused on self-innovation and enhancing its R&D capabilities, with a total of 45 new product registrations in H1 2025, including 26 new registrations for domestic and international products [2] - The R&D personnel count reached 187, a year-on-year increase of 47.24%, with 42.25% holding bachelor's degrees and 40.11% holding master's degrees or higher [2] Future Outlook - The net profit attributable to shareholders is projected to be 327 million yuan, 387 million yuan, and 464 million yuan for 2025, 2026, and 2027, respectively, with growth rates of 11.6%, 18.1%, and 19.8% [3]

Core Viewpoint - Anjisi reported a decrease in the number of shareholders and a slight increase in stock price, while also showing a decline in financing balance and mixed performance in stock price movements since the concentration of shares began [2]. Group 1: Shareholder and Stock Performance - As of September 20, the number of shareholders for Anjisi was 4,779, a decrease of 856 from the previous period, representing a decline of 15.19% [2]. - The closing price of Anjisi on the reporting date was 73.13 yuan, up by 0.45%, but the stock price has cumulatively decreased by 1.59% since the concentration of shares began, with 3 days of increase and 5 days of decrease [2]. Group 2: Financing and Revenue - The latest margin trading data as of September 19 shows a total margin balance of 10.3 million yuan, with a financing balance of 10.3 million yuan, reflecting a decrease of 4.20% or 4.5318 million yuan since the concentration of shares began [2]. - In the first half of the year, Anjisi achieved operating revenue of 302 million yuan, a year-on-year increase of 14.56%, and a net profit of 126 million yuan, also a year-on-year increase of 1.26%, with basic earnings per share at 1.5562 yuan and a weighted average return on equity of 5.12% [2]. Group 3: Institutional Ratings - Over the past month, Anjisi received buy ratings from three institutions, with the highest target price set at 112.69 yuan by Guotou Securities on September 14 [2].

杭州安杰思医学科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年第二次临时股东大会 会议资料 2025 年 09 月 | 2025 | 年第二次临时股东大会会议须知 1 | | --- | --- | | 2025 | 年第二次临时股东大会会议议程 3 | | 2025 | 年第二次临时股东大会会议议案 5 | | 议案一 | 5 | | 关于取消监事会并修订《公司章程》及办理工商变更登记的议案 5 | | | 议案二 | 7 | | 关于制定、废止、修订部分公司治理制度的议案 | 7 | 证券代码：688581 证券简称：安杰思 杭州安杰思医学科技股份有限公司 杭州安杰思医学科技股份有限公司 2025 年第二次临时股东大会会议资料 杭州安杰思医学科技股份有限公司 2025 年第二次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东大会议事规 则》等有关规定，特制定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作,为确认出席大会的股东 或其代理人或其他出席者的出席资格，会议工作人 ...

Core Insights - As of September 12, a total of 106 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stocks with the longest streak of net buying are Wankai New Materials and Changjiang Media, both having received net buying for 13 consecutive trading days [1] - Other notable stocks with significant net buying days include Haotaitai, Tianpu Co., Xinquan Co., Anjiasi, Feike Electric, Bowei Alloy, Zhongyuan Home, and Jianfeng Group [1]

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a target price of 112.69 CNY for the next six months [5][8]. Core Insights - The company is positioned as a leading domestic player in the high-growth endoscope market, with significant potential for overseas expansion and improvements in domestic procurement policies [1][2][4]. - The global endoscope market is projected to exceed 30 billion USD by 2026, with a compound annual growth rate (CAGR) of approximately 7% for endoscopic consumables [2][25]. - The company has a comprehensive product line in endoscopic consumables, aligning closely with international competitors, and is transitioning towards becoming a comprehensive supplier in the endoscopy field [1][15]. Summary by Sections Company Overview - The company has achieved full coverage of major categories in the endoscopic consumables sector, including hemostatic closure, EMR/ESD, biopsy, ERCP, and diagnostic instruments, with industry-leading technological innovation capabilities [1][15]. - The company is expanding its pipeline of products under development, aiming to transition into a comprehensive endoscopic solutions provider [1][20]. Global Market Potential - The global endoscope market is expected to grow significantly, with the 2023 market size estimated at 25 billion USD and projected to reach over 30 billion USD by 2026 [2][25]. - The company has rapidly developed its overseas business, achieving 330 million CNY in overseas revenue in 2024, with a CAGR of 34% from 2019 to 2024 [2][3]. Domestic Market Dynamics - The domestic medical endoscope market is expected to exceed 50 billion CNY by 2032, with a projected CAGR of 8.7% over the next decade [4][10]. - Recent procurement policy optimizations are expected to benefit innovative domestic leaders like the company, enhancing market order and supporting high-quality products [4][10]. Financial Projections - The company is expected to achieve revenue growth rates of 24.8%, 25.0%, and 22.8% for the years 2025 to 2027, with net profit growth rates of 14.5%, 15.8%, and 15.3% respectively [8][10]. - The company's revenue for 2024 is projected to be 637 million CNY, with a net profit of 293 million CNY, reflecting strong growth despite short-term procurement pressures [20][21].